Adocia opens a subsidiary in the USA
Adocia announced the creation of a subsidiary in the USA, Adocia Incorporated, and the accompanying appointments of Simon Bruce, MD and Stephen Daly. Opening a US subsidiary is a key step in Adocia's strategy, the USA are currently the primary market for its products
Two employees are already appointed, Simon Bruce, M.D., Chief Medical Officer and Stephen Daly, US Commercial Lead who is in charge of the business development in the USA and also of the US investors relations.
Dr. Bruce, who originally trained in endocrine clinical research at the National Institutes of Health in Bethesda, MD, has over 15 years of experience drug development and registrational drug trials. In his last job at Halozyme Pharmaceuticals, Dr Bruce held a position as an Executive Medical Director working on the ultra-rapid insulin program. He was in charge of the regulatory strategy and led numerous interactions with the Food and Drug Administration (FDA). Previously at Amylin Pharmaceuticals, he was in charge of the phase 3 studies and safety analysis in the development in the USA of Bydureon, which is a once-weekly GLP-1 analog injectable formulation.
Stephen Daly has 24 years of experience in commercialization and business development for pharmaceutical and biotech products across multiple therapeutic categories. Most recently, he served as the Vice President of Commercial at Halozyme Therapeutics for their ultra-rapid insulin program. Stephen Daly's experience in the diabetes field also includes several years at Amylin Pharmaceuticals in marketing and brand leadership for Byetta® and Symlin®
Other news from the department business & finance
